title: Therapeutic management of ocular adnexal MALT lymphoma.
abstract: Non-Hodgkin lymphomas constitute 50% of all orbital malignancies. Mucosa-associated lymphoid tissue (MALT)-type lymphoma is the most common histology category in this anatomic region. Ocular adnexal lymphoma of MALT-type is an indolent and rarely lethal malignancy that can often be managed with observation alone. Occasionally, lymphomatous lesions determine the symptoms that condition a patient's quality of life, and so require an immediate antineoplastic treatment. Several strategies are available, but reliable indications supported by prospective trials do not exist. Some therapeutic strategies are associated with substantial side effects and require a well-balanced therapeutic decision, which should take into account several variables related to the patient, the lymphoma, and the treatment itself. In this review, the authors analyze related literature and propose therapeutic guidelines for the management of ocular adnexal lymphoma of MALT-type.
authors.affiliation: Medical Oncology Unit, Department of Oncology, San Raffaele Scientific Institute, Via Olgettina 6020132, Milan, Italy. ferreri.andres@hsr.it
authors.forename: Andres J M
authors.initials: AJ
authors.lastname: Ferreri
authors.forename: Andrea
authors.initials: A
authors.lastname: Assanelli
authors.forename: Roberto
authors.initials: R
authors.lastname: Crocchiolo
authors.forename: Giuseppina P
authors.initials: GP
authors.lastname: Dognini
authors.forename: Antonio Giordano
authors.initials: AG
authors.lastname: Resti
authors.forename: Letterio S
authors.initials: LS
authors.lastname: Politi
authors.forename: Claudio
authors.initials: C
authors.lastname: Doglioni
authors.forename: Federico Caligaris
authors.initials: FC
authors.lastname: Cappio
authors.forename: Riccardo
authors.initials: R
authors.lastname: Dolcetti
authors.forename: Maurilio
authors.initials: M
authors.lastname: Ponzoni
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D005134:Eye Neoplasms / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000209:etiology / Q000473:pathology / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents